



Attorney Docket No. 50225-8068.US00

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: January 18, 2002

By: Lynna Anderson

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Singh, et al.

EXAMINER: Unknown

SERIAL No.: 09/903,290

ART UNIT: 1743

FILED: July 11, 2001

FOR: TAG CLEAVAGE FOR DETECTION OF  
NUCLEIC ACIDS

COPY OF PAPERS  
ORIGINALLY FILED

Preliminary Amendment

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination, applicants respectfully request entry of the following amendments.

In the specification:

Please replace the paragraph bridging pages 13 and 14 with the following:

--

Target: . . . CGCAA TAGCC TAGCA GT (c) GC . . . (SEQ ID NO: 1)  
. . . GCGTT ATCGG ATCGT CA (g) CG . . .

Primer: 5'- CGCAATAGCCTAGCCACTTG-3' (SEQ ID NO: 2)

Probe: \*ACLA001-5'-CAAGTCGTcGC -3' (SEQ ID NO: 3)

^

\* eTag fluorescent group: Fluorescein(C<sub>6</sub>P), (ACLA001)

^ indicates site of cleavage

c indicates base complementary to SNP locus--

Please replace the paragraph bridging pages 15 and 16 with the following:

--  
Target #1:

Target: . . . CTAGCACT (c/g) G CAGGATACTG ACCTGCGC. . . (SEQ ID NO: 4)  
. . . GATCGTCA (g/c) C GTCCTATGAC TGGACGCG . . .

Primer: 5'-CAAGTCGGAT ACTGACCTGC AT-3' (SEQ ID NO: 5)

Probes: 5'-GT<sup>c</sup>GCCACTT G-3'-ACLA001\* (SEQ ID NO: 6)

5'-GT<sup>g</sup>GCCACTT G-3'-ACLA016\* (SEQ ID NO: 7)

--  
Target #2:

Target: . . . GAGATCCA (c/g) CAGCA AAGTC CGAGT CGGT . . . (SEQ ID NO: 8)  
. . . CTCTAGGT (g/c) GTCGT TTCAG GCTCA GCCA . . .

Primer: 5'-CAAGTACCAA AGTCCGAGTC GAA -3' (SEQ ID NO: 9)

Probes: 5'-CA<sup>c</sup>CACTACT TG-3'-ACLA018\* (SEQ ID NO: 10)

5'-CA<sup>g</sup>CACTACT TG-3'-ACLA019\* (SEQ ID NO: 11)

\* indicates eTag fluorescent groups(all containing Fluorescein):

ACLA001: F1(C<sub>6</sub>P)<sub>1</sub>-oligonucleotide

ACLA016: F1(C<sub>6</sub>P)<sub>1</sub>(C<sub>3</sub>P)<sub>1</sub>-oligonucleotide

ACLA018: F1(C<sub>6</sub>P)<sub>1</sub>(C<sub>3</sub>P)<sub>2</sub>-oligonucleotide

ACLA019: F1(C<sub>6</sub>P)<sub>1</sub>(C<sub>3</sub>P)<sub>3</sub>-oligonucleotide

^ indicates site of cleavage

c or g indicates base complimentary to SNP locus--

Attorney Docket No. 50225-8068.US00

In the specification after page 17, insert pages 1-3 enclosed herewith.

REMARKS

Entry of the above amendment prior to examination is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with Markings to Show Changes Made".

The specification has been amended in accordance with 37 C.F.R. §§ 1.821 through 1.825 to add the Sequence Listing.

The specification has further been amended for compliance with the requirements of 37 C.F.R. § 1.821(d). Specifically, the amino acid and/or nucleotide sequences disclosed in the specification are now identified by SEQ ID NOS.

In light of the foregoing amendment to the application, applicants submit that the application is now in full compliance with 37 C.F.R. §§ 1.821 through 1.825.

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4410.

Respectfully submitted,

*Jacqueline F. Mahoney*  
Jacqueline F. Mahoney  
Registration No. 48,390

Date: January 13, 2007

Correspondence Address:

Customer No. 22918